<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="fluid retention113. Additional mechanisms, such as a reduction of endothelial" exact="nitric oxide" post="synthase activity and nitric oxide levels, as well as"/>
 <result pre="as a reduction of endothelial nitric oxide synthase activity and" exact="nitric oxide" post="levels, as well as the release of vascular endothelial"/>
 <result pre="antiviral agents. Of the repurposed antivirals investigated to date, the" exact="adenosine" post="analogue remdesivir was initially identified as a promising therapy"/>
 <result pre="patient groups such as kidney transplant recipients. The anti-malaria drug" exact="hydroxychloroquine" post="has also been investigated for its ability to inhibit"/>
 <result pre="However, available evidence does not support a beneficial effect of" exact="hydroxychloroquine" post="over standard therapy in treating mild-to-moderate disease201, nor as"/>
 <result pre="post-exposure prophylaxis strategy202. Moreover, two clinical trials have shown that" exact="hydroxychloroquine" post="treatment poses serious safety concerns, increasing the risk of"/>
 <result pre="shedding207. However, early reports from China indicated that treatment with" exact="methylprednisolone" post="decreased the risk of death of patients with COVID-19"/>
 <result pre="A preliminary study found that an early, short course of" exact="methylprednisolone" post="therapy improved outcomes of adult patients with COVID-19 with"/>
 <result pre="with SARS-CoV-2 infection122. A large randomized controlled trial showed that" exact="dexamethasone" post="reduced 28-day mortality in severely ill patients who were"/>
 <result pre="those receiving no respiratory support216. These findings are encouraging since" exact="dexamethasone" post="treatment is also highly beneficial in patients with pre-existing"/>
 <result pre="COVID-19 patients with a synthetic biological immune response modifier, thymosin" exact="alpha" post="1 (ref.232), effectively restored CD8+ and CD4+ T cell"/>
 <result pre="CD8+ T cells233. Compared with untreated patients, supplementation of thymosin" exact="alpha" post="1 in COVID-19 patients with severe lymphocytopenia was associated"/>
 <result pre="promising approach than LMWH may be the serine protease inhibitor" exact="nafamostat" post="mesylate, which is under investigation in four different clinical"/>
 <result pre="showed that prophylactic anti-coagulation therapy supplemented by the anti-platelet drug" exact="dipyridamole" post="prevented the progression of COVID-19 to severe stages of"/>
 <result pre="levels243. Notably, through virtual screening of an approved drug library," exact="dipyridamole" post="was also found to suppress SARS-CoV-2 replication in vitro243."/>
 <result pre="coronavirus infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 201.CavalcantiABet al.Hydroxychloroquine with or without" exact="azithromycin" post="in mild-to-moderate Covid-19N. Engl. J. Med.202010.1056/NEJMoa201901432706953 202.BoulwareDRet al.A randomized"/>
 <result pre="mild-to-moderate Covid-19N. Engl. J. Med.202010.1056/NEJMoa201901432706953 202.BoulwareDRet al.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19N. Engl. J. Med.202038351752510.1056/NEJMoa201663832492293 203.MagagnoliJet"/>
 <result pre="postexposure prophylaxis for Covid-19N. Engl. J. Med.202038351752510.1056/NEJMoa201663832492293 203.MagagnoliJet al.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19Med202010.1016/j.medj.2020.06.00132838355 204.BorbaMGSet"/>
 <result pre="with Covid-19Med202010.1016/j.medj.2020.06.00132838355 204.BorbaMGSet al.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
 <result pre="210.ShangLZhaoJHuYDuRCaoBOn the use of corticosteroids for 2019-nCoV pneumoniaLancet202039568368410.1016/S0140-6736(20)30361-532122468 211.BlumCAet al.Adjunct" exact="prednisone" post="therapy for patients with community-acquired pneumonia: a multicentre, double-blind,"/>
 <result pre="covid-19 â€&quot; preliminary reportN. Engl. J. Med.202010.1056/NEJMoa2021436 217.JacobKAet al.Intraoperative high-dose" exact="dexamethasone" post="and severe AKI after cardiac surgeryJ. Am. Soc. Nephrol.2015262947295110.1681/ASN.201408084025952257"/>
 <result pre="pitfalls and pearlsClin. J. Am. Soc. Nephrol.20181381582210.2215/CJN.1299111729475991 219.DusheikoGSide effects of" exact="alpha" post="interferon in chronic hepatitis CHepatology199726112S121S10.1002/hep.5102607209305675 220.AlattarRet al.Tocilizumab for the"/>
 <result pre="clinical applications of thymosin Î±1Expert Opin. Biol. Ther.2009959360810.1517/1471259090291141219392576 233.LiuYet al.Thymosin" exact="alpha" post="1 (TÎ±1) reduces the mortality of severe COVID-19 by"/>
 <result pre="240.US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT04418128 (2020). 241.YamamotoMet al.Identification of" exact="nafamostat" post="as a potent inhibitor of Middle East respiratory syndrome"/>
 <result pre="the split-protein-based cell-cell fusion assayAntimicrob. Agents Chemother.2016606532653910.1128/AAC.01043-1627550352 242.AnsarinKet al.Effect of" exact="bromhexine" post="on clinical outcomes and mortality in COVID-19 patients: a"/>
 <result pre="patients: a randomized clinical trialBioimpacts20201020921510.34172/bi.2020.2732983936 243.LiuXet al.Potential therapeutic effects of" exact="dipyridamole" post="in the severely ill patients with COVID-19Acta Pharm. Sin."/>
</results>
